8-K: TriSalus Reports Strong 2025 Revenue, Reaffirms 2026 Guidance

TriSalus Life Sciences announced robust fourth quarter and full-year 2025 financial results, exceeding revenue guidance and reaffirming its 2026 outlook, bolstered by a recent $46 million public offering.

Summary

• Fourth quarter 2025 revenue reached $13.2 million, a 60% year-over-year increase and 14% sequential growth over the third quarter 2025.
• Full-year 2025 revenue was $45.2 million, up 53% from 2024, exceeding the company's 50% guidance.
• Reaffirmed 2026 revenue guidance of $60 million to $62 million.
• Adjusted EBITDA loss improved significantly to $0.9 million in Q4 2025 from $5.7 million in Q4 2024, and to $17.2 million for full-year 2025 from $30.0 million in 2024.
• Strengthened balance sheet with $46 million in gross proceeds from a public offering subsequent to the fourth quarter.
• Launched the TriNav XP Infusion System, engineered for compatibility with larger embolic particles and improved trackability.
• Appointed veteran healthcare investor Michael Stansky to the Board of Directors in February 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong revenue growth exceeding guidance and improved operational efficiency (Adjusted EBITDA). The successful capital raise and reaffirmed 2026 guidance provide a solid foundation, despite increased net losses due to non-operational factors like preferred stock conversion.

Positives

• Exceeded 2025 revenue guidance, achieving 53% growth against a 50% target.
• Strong revenue growth in Q4 2025 (60% year-over-year) and full-year 2025 (53% year-over-year).
• Improved gross margin in Q4 2025 to 86.7% from 85.3% in Q4 2024.
• Significant improvement in Adjusted EBITDA loss for both Q4 2025 (to $0.9 million from $5.7 million) and full-year 2025 (to $17.2 million from $30.0 million).
• Successful public offering raising $46 million in gross proceeds to support growth initiatives.
• Operating losses decreased to $26.9 million for FY 2025 from $36.2 million in FY 2024, indicating strong operating leverage.
• Expansion of TriNav use in liver embolization and continued development of new applications for new clinical settings.
• Launch of the TriNav XP Infusion System enhances the product portfolio and expands capabilities.
• Research and Development (R&D) expenses decreased by $2.7 million for FY 2025 due to the close-out of clinical trial expenses related to nelitolimod.

Negatives

• Full-year 2025 gross margin decreased to 84.6% from 86.1% in 2024, primarily due to lower manufacturing efficiency associated with newly launched products.
• Net loss attributable to common stockholders increased significantly to $69.7 million for FY 2025 from $33.2 million in FY 2024, primarily driven by the conversion of preferred stock to common stock.
• Basic and diluted loss per share increased to $1.84 for FY 2025 from $1.31 in FY 2024, primarily due to the conversion of preferred stock.
• Sales and Marketing (S&M) expenses increased by $2.9 million for FY 2025, primarily due to an increase in performance-related compensation driven by higher sales.
• General & Administrative (G&A) expenses increased by $3.5 million for FY 2025, primarily due to the acceleration of a non-cash stock-based compensation award and reclassification of patent-related expenses.

Risks

• Risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the company's clinical trials.
• Uncertainty regarding the cost and timing of all development activities and clinical trials.
• Potential for unexpected safety and efficacy data observed during clinical studies.
• Risks associated with the credit facility, including the company's ability to remain in compliance with all its obligations thereunder to avoid an event of default.
• Risk that the company will continue to raise capital through the issuance and sale of its equity securities to fund its operations.
• Risk that the company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility.
• Risk that the company will not become profitable on its expected timeline, if at all.
• Risk that the reported financial results will differ from the estimates provided.
• Changes in expected or existing competition or market conditions.
• Changes in the regulatory environment.
• Unexpected litigation or other disputes.
• Unexpected expensed costs.

Future Outlook

The company reaffirms its 2026 revenue guidance in the range of $60 million to $62 million. Strategic plans for 2026 include deepening engagement within the interventional radiology community, expanding sales and commercial organizations, investing in foundational registry and clinical studies to demonstrate the value of the PEDD platform, and continuing to advance innovative PEDD product launches that enhance and differentiate the embolization toolkit. The $46 million in growth capital raised through the recent public offering is expected to substantially broaden and accelerate these strategic initiatives and drive broader adoption of the PEDD platform.

Management Comments

• "During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, supported by the growing clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications." Mary Szela, President and CEO of TriSalus.
• "We are pleased to have exceeded our 2025 revenue guidance of 50%, delivering 53%, reflecting strong commercial execution and sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver." Mary Szela, President and CEO of TriSalus.
• "The $46 million in growth capital raised through our recent public offering, will substantially broaden and accelerate these strategic initiatives and drive support broader adoption of the PEDD platform." Mary Szela, President and CEO of TriSalus.
• "Based on our performance and positive outlook for 2026, we are reaffirming our revenue guidance of $60 million to $62 million." Mary Szela, President and CEO of TriSalus.
• "We look forward to 2026 confident in the commercial opportunities before us and energized by our long-term vision of bringing our PEDD technology to a wider range of patients and improving clinical outcomes." Mary Szela, President and CEO of TriSalus.

Industry Context

StockSavvy.ai notes that TriSalus's focus on integrating novel delivery technology with standard-of-care therapies and investigational immunotherapeutics positions it within a growing segment of oncology, where precision drug delivery and combination therapies are becoming increasingly vital. The expansion of the TriNav platform beyond liver indications and into areas like uterine fibroids and thyroid disease reflects a broader trend in medical technology to leverage existing platforms for new applications, potentially expanding market reach and addressing unmet needs in various interventional radiology settings. The company's continued investment in clinical studies and product innovation aligns with industry efforts to enhance patient outcomes through advanced medical devices.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, exceeding guidance, improved Adjusted EBITDA, and a successful capital raise. Negative impact from increased net loss and loss per share due to preferred stock conversion, which dilutes existing common stockholders.
• Employees: Potential positive impact from expansion of sales and commercial organizations, possibly leading to new hires or growth opportunities. Increased Sales and Marketing expenses due to performance-related compensation suggest positive incentives for sales teams.
• Customers (Healthcare Providers): Positive impact from the launch of new products like TriNav XP and continued investment in clinical studies, potentially offering improved treatment options and broader applications for the PEDD platform.
• Creditors: The $46 million capital raise strengthens the balance sheet, potentially reducing immediate credit risk, though the company still carries long-term debt and faces risks related to credit facility compliance.

Next Steps

• Deepen engagement within the interventional radiology community by expanding sales and commercial organizations.
• Invest in foundational registry and clinical studies to further demonstrate the value of PEDD in the liver and new applications.
• Continue to advance innovative PEDD product launches that enhance and differentiate the embolization toolkit.
• Explore partnership opportunities for the development of nelitolimod, following final stages of data completion for Phase 1 clinical trials.
• Host a conference call and webcast on March 5, 2026, to discuss financial results for the quarter and year ended December 31, 2025.

Key Dates

Recommendation

While TriSalus demonstrated strong revenue growth exceeding guidance and improved operational efficiency (Adjusted EBITDA), the significant increase in net loss and loss per share due to preferred stock conversion introduces a notable negative. The recent capital raise strengthens the balance sheet and supports future initiatives, but the company remains unprofitable and faces various clinical and market risks. The reaffirmation of 2026 guidance is positive, but the stock warrants a 'hold' as investors assess the long-term path to profitability and the impact of dilution from the preferred stock conversion, balancing strong commercial performance against increased losses.

Keywords

TriSalus Life Sciences, TLSI, Oncology, Medical Technology, SEC Filing, Earnings Report, Q4 2025 Results, Full-Year 2025 Results, Revenue Guidance, PEDD Platform, TriNav System, Immunotherapy, Nelitolimod, Solid Tumors, Interventional Radiology, Financial Results, Biotech, Medical Devices, Capital Raise